Amylyx Pharmaceuticals (AMLX) Projected to Post Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. On average, analysts expect Amylyx Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ:AMLX traded down $0.13 during midday trading on Tuesday, hitting $5.03. 95,293 shares of the stock were exchanged, compared to its average volume of 1,225,351. The business's fifty day simple moving average is $3.92 and its two-hundred day simple moving average is $4.22. Amylyx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $7.27. The company has a market capitalization of $447.65 million, a PE ratio of -1.31 and a beta of -0.60.

Analyst Ratings Changes

A number of research firms recently commented on AMLX. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Mizuho upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and increased their price target for the stock from $3.00 to $7.00 in a research note on Monday, April 7th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.00.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 21,490 shares of the company's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $3.47, for a total transaction of $74,570.30. Following the completion of the sale, the chief executive officer now directly owns 3,355,280 shares in the company, valued at $11,642,821.60. This represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was acquired at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at $37,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 48,980 shares of company stock valued at $168,627 over the last 90 days. 11.70% of the stock is currently owned by company insiders.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.